You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Topically applied imiquimod 5% cream cleared actinic keratosis lesions

https://doi.org/10.1136/ebm.10.1.11

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004;50:714–21.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In patients with actinic keratoses (AK), is a topically applied imiquimod 5% cream more effective than placebo for clearing lesions?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Dermatology ★★★★★★☆

    METHODS

    Embedded ImageDesign:

    2 concurrent randomised controlled trials subsequently merged into 1 trial for data analysis purposes.

    Embedded ImageAllocation:

    concealed.*

    Embedded ImageBlinding:

    blinded (patients, healthcare providers, data collectors, outcome assessors, data analysts, and the sponsor).*

    Embedded ImageFollow up period:

    16 weeks of treatment followed by an 8 week observational period.

    Embedded ImageSetting:

    24 centres in the US and Canada.

    Embedded ImagePatients:

    436 otherwise healthy people >18 years of age (mean age 66 y, 87% men) who had 4–8 clinically diagnosed AK lesions within a contiguous 25 cm2 treatment area on the face …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • For correspondence: Dr M Lebwohl, Mount Sinai School of Medicine, New York, NY, USA. Lebwohl{at}aol.com

    • Source of funding: not stated.